Safety profile of enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma: a multicenter Japanese cohort study.
Sign Up to like & getrecommendations! Published in 2025 at "Japanese journal of clinical oncology"
DOI: 10.1093/jjco/hyaf182
Abstract: INTRODUCTION Enfortumab vedotin plus pembrolizumab (EVP) has shown promising efficacy in locally advanced or metastatic urothelial carcinoma (la/mUC), but real-world data in Japanese patients are limited. We assessed the safety and early efficacy of EVP,… read more here.
Keywords: metastatic urothelial; enfortumab vedotin; vedotin plus; advanced metastatic ... See more keywords
A phase 3 study comparing polatuzumab vedotin plus R-CHP versus R-CHOP in patients with DLBCL (POLARIX).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps7589
Abstract: TPS7589Background: R-CHOP remains the standard of care in patients (pts) with previously untreated diffuse large B-cell lymphoma (DLBCL). However, pts with high-risk disease have poorer outcomes wi... read more here.
Keywords: comparing polatuzumab; study comparing; vedotin plus; phase study ... See more keywords
Enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma: First results on outcomes and safety in a German multicenter real-world patient cohort (GUARDIANS).
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.5_suppl.715
Abstract: 715 Background: The prospective phase 3 study EV-302 demonstrated superiority regarding efficacy of Enfortumab vedotin plus Pembrolizumab (EVP) compared to platinum-based chemotherapy in patients (pts) that received first-line (1L) therapy for metastatic urothelial carcinoma (mUC).… read more here.
Keywords: oncology; cohort; enfortumab vedotin; vedotin plus ... See more keywords